Tardio Jason 4
4 · Ovid Therapeutics Inc. · Filed Apr 12, 2022
Insider Transaction Report
Form 4
Tardio Jason
Chief Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-04-08+87,498→ 87,498 totalExercise: $3.22Exp: 2023-04-07→ Common Stock (87,498 underlying) - Award
Stock Option (Right to Buy)
2022-04-08+10,000→ 10,000 totalExercise: $3.22Exp: 2023-04-07→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- [F2]The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on April 8, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous services through such vesting date.